In fact, subcutaneously administered immunoglobulin therapy (scIgRT) at high doses decreased CD83 expression with consequential inhibition of B-cell receptor (BCR) signalling and reduced TNF-α production with in-vitro studies showing an associated decrease in the survival of CLL cells (9). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.